NCT02454504.

Trial name or title	Quality of awakening and impact on cognitive function after administration of sugammadex in robotic radical cystectomy
Methods	Allocation: randomized Intervention model: parallel assignment Masking: open‐label
Participants	Estimated enrolment: 60 Inclusion criteria: ASA score ≤ III Underwent robotic cystectomy Exclusion criteria: Cerebrovascular disease BMI ≥ 30
Interventions	Sugammadex at completion of surgery Neostigmine at completion of surgery
Outcomes	Primary outcome measures: Average score obtained on awakening according to specific test [Time Frame: 16 months] [Designated as safety issue: yes] Cognitive function as assessed by the Mini‐Mental State Exam; quality of awakening as assessed by the Observer's Assessment of Alertness/Sedation
Starting date	March 2014
Contact information	Ester Forastiere, Dr, 0039 06 52662995: forastiere@ifo.it Regina Elena Cancer Institute Rome, RM, Italy, 00144 Sub‐Investigator: Claudia Claroni, MD
Notes	This study is currently recruiting participants. Estimated Primary Completion Date: December 2016